Jun 18, 2024 | Press Releases
Phio’s Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts–(Newsfile Corp. – June 18, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose...
May 28, 2024 | Press Releases
Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts–(Newsfile Corp. – May 28, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage...
May 23, 2024 | Press Releases
Phio to present a clinical study progress update on their lead clinical candidate, PH-762Marlborough, Massachusetts–(Newsfile Corp. – May 23, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
May 17, 2024 | Press Releases
–Fund invests in microcap equitiesMARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make...
May 16, 2024 | Press Releases
-Phio’s lead candidate, PH-762, targets PD-1, a critical target in cutaneous carcinomaMARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™...
